Erasca inc ERAS.US Value Analysis
US StockHealth Care
(No presentation for ERAS)
ERAS Value Score
3
24
15
Limited Growth
- AI analysis rates ERAS with a lower value score of 2.
- It is mainly due to unstable operating cash flow, along with potential value may be lower.
- Over the past 3 months, ERAS has maintained a consecutive value rating of 2.0, higher than the rating of 0.4 over the past 3 years, indicating increasing opportunities for enterprise value growth.
- Compared to all stocks in the Health Care sector, ERAS has a medium value rating.
ERAS Value Reference Factors
The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.
No related data records
Update to 2025/03/27 (Weekly Update)
ERAS Financial Forecast
Unit : USD
Update to 2025/5/4 (Quarterly Update)
ERAS Earnings Table
No related data records
ERAS Historical Value Score
You can use historical scores of 3 or above to observe potential performance and make investment decisions.
ERAS Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
Entry
Exit
The Backtest Result of ERAS from 2021/07 till Now
- -
- Cumulative Return
- -
- Annual Return
- -
- Volatility
- -
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from July, 2021 to May, 2025. (Total Trades: 0)
| ERAS | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | - | 44% | 53% |
| Avg Return | - | 63.1% | 72.3% |
| Avg Profit | - | 198.4% | 166.4% |
| Avg Loss | - | -44.8% | -34.6% |
| Avg Risk-Reward Ratio | - | 442.5% | 480.4% |
Update to 2025/5/8 (Daily Update)